Literature DB >> 2240351

Incorporation of pyrazinamide into community-wide treatment of tuberculosis.

C M Nolan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2240351      PMCID： PMC1405113          DOI： 10.2105/ajph.80.12.1525

Source DB:  PubMed          Journal:  Am J Public Health        ISSN： 0090-0036            Impact factor:   9.308


× No keyword cloud information.
  3 in total

1.  A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.

Authors:  D L Cohn; B J Catlin; K L Peterson; F N Judson; J A Sbarbaro
Journal:  Ann Intern Med       Date:  1990-03-15       Impact factor: 25.391

2.  The National Tuberculosis Training Initiative.

Authors:  L B Reichman
Journal:  Ann Intern Med       Date:  1989-08-01       Impact factor: 25.391

3.  USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.

Authors:  D L Combs; R J O'Brien; L J Geiter
Journal:  Ann Intern Med       Date:  1990-03-15       Impact factor: 25.391
  3 in total
  2 in total

1.  Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.

Authors:  Laura E Via; Rada Savic; Danielle M Weiner; Matthew D Zimmerman; Brendan Prideaux; Scott M Irwin; Eddie Lyon; Paul O'Brien; Pooja Gopal; Seokyong Eum; Myungsun Lee; Jean-Philippe Lanoix; Noton K Dutta; TaeSun Shim; Jeong Su Cho; Wooshik Kim; Petros C Karakousis; Anne Lenaerts; Eric Nuermberger; Clifton E Barry; Véronique Dartois
Journal:  ACS Infect Dis       Date:  2015-05-08       Impact factor: 5.084

Review 2.  The need for epidemic intelligence.

Authors:  A B Bloch; I M Onorato; W W Ihle; J L Hadler; C H Hayden; D E Snider
Journal:  Public Health Rep       Date:  1996 Jan-Feb       Impact factor: 2.792
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.